StevanatoSTVN
STVN
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
9% more capital invested
Capital invested by funds: $1.08B [Q3] → $1.18B (+$102M) [Q4]
5% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 44
0.44% more ownership
Funds ownership: 109.38% [Q3] → 109.82% (+0.44%) [Q4]
0% more funds holding
Funds holding: 128 [Q3] → 128 (+0) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
71% less call options, than puts
Call options by funds: $15K | Put options by funds: $52K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$24
12%
upside
Avg. target
$24
12%
upside
High target
$24
12%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
UBS John Sourbeer 33% 1-year accuracy 1 / 3 met price target | 12%upside $24 | Neutral Maintained | 7 Mar 2025 |
Financial journalist opinion
Based on 5 articles about STVN published over the past 30 days
Neutral
Business Wire
2 weeks ago
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company will present on Tuesday, March 18, at 3.00 p.m. (ET). A live webcast will be available on the Company.

Negative
Seeking Alpha
3 weeks ago
Stevanato: Ramping Syringe Demand, Buy Confirmed
Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war.

Neutral
Seeking Alpha
3 weeks ago
Stevanato Group S.p.A. (STVN) Q4 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Lisa Miles - SVP, IR Franco Stevanato - Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Michael Ryskin - Bank of America Matt Larew - William Blair Patrick Donnelly - Citi David Windley - Jefferies Pete Lukas - CJS Securities Anna Snopkowski - KeyBanc Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Operator Good afternoon.

Positive
Zacks Investment Research
3 weeks ago
Stevanato Group (STVN) Meets Q4 Earnings Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.20 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.19 per share a year ago.

Neutral
Business Wire
3 weeks ago
Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period) Revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represent.

Neutral
Business Wire
1 month ago
Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 6, 2025,.

Positive
Zacks Investment Research
1 month ago
USNA or STVN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

Neutral
Zacks Investment Research
2 months ago
USNA vs. STVN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Positive
Zacks Investment Research
2 months ago
UTHR vs. STVN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?

Neutral
Business Wire
2 months ago
Stevanato Group to Present at Upcoming Investor Conference
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET. A live event webcast will be available on the Company's website at www.stevanatogroup.com under the "Investors" sec.

Charts implemented using Lightweight Charts™